Watch for Adbry, Cibinqo, and Rinvoq for Eczema

March 2022

More meds for moderate to severe atopic dermatitis will try to squeeze into the market...Adbry, Cibinqo, and Rinvoq.

Save these specialty meds for when topicals (steroids, etc) aren’t enough. Include these in the EHR, even if you’re not prescribing them.

Adbry (tralokinumab) is similar to Dupixent (dupilumab). Both are injectable monoclonal antibodies that reduce inflammation.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Immunizations Clarify New Guidelines for Prevnar 20 and Vaxneuvance
Corticosteroids Be Equipped With Rules of Thumb to Taper Steroids
Insulin Implement Safeguards for U-500 Insulin
Mental Health Be Ready to Ask Questions About Suicide
Pediatrics Shorten Antibiotic Durations for Kids With Community-Acquired Pneumonia
Neurology & Pain Compare Meds for Diabetic Neuropathy
Oral Health Reinforce Oral Care With Buccal or Sublingual Buprenorphine
Insomnia Be Prepared With Answers About Melatonin for Sleep
Eczema Watch for Adbry, Cibinqo, and Rinvoq for Eczema
Infectious Diseases Optimize Antibiotic Stewardship for Gram-Negative Bacteremia
COVID-19 Assess the Role of the New COVID-19 MAb, Bebtelovimab
Critical Care Prevent Withdrawal Due to ICU Analgesics and Sedatives